Vitura HealthASX:VIT Return-on-Tangible-Equity is -24.24% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 897 Drug Manufacturers companies, Vitura Health ranks better than 57.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vitura Health's annualized net income for the quarter that ended in Dec. 2025 was A$-1.7 Mil. Vitura Health's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$6.9 Mil. Therefore, Vitura Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -24.24%.
The historical rank and industry rank for Vitura Health's Return-on-Tangible-Equity or its related term are showing as below:
ASX:VIT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -37.22 Med: 31.35 Max: 58.99
Current: 10.39
During the past 7 years, Vitura Health's highest Return-on-Tangible-Equity was 58.99%. The lowest was -37.22%. And the median was 31.35%.
ASX:VIT's Return-on-Tangible-Equity is ranked better than 57.75% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs ASX:VIT: 10.39
Vitura Health (ASX:VIT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vitura Health Return-on-Tangible-Equity Related Terms
Vitura Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vitura Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VIT vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vitura Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -24.24% mean?
Vitura Health (ASX:VIT) has a Return-on-Tangible-Equity of -24.24% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vitura Health and its competitors. According to the industry distribution chart, Vitura Health ranks #379 out of 897 companies in the Drug Manufacturers industry, placing it in the top 42.3%.
Is Vitura Health's Return-on-Tangible-Equity too high?
Vitura Health's current Return-on-Tangible-Equity is -24.24%. Based on the distribution chart, Vitura Health ranks #379 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Vitura Health's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #379 out of 897 companies for Return-on-Tangible-Equity. This puts Vitura Health in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Return-on-Tangible-Equity is -24.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current Return-on-Tangible-Equity is -24.24%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Return-on-Tangible-Equity is -24.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 